bigger Created with Sketch.

News & Events

News & Events

To sign up for news alerts, please e-mail info@homologymedicines.com

For media inquiries, please email cmayfield@homologymedicines.com

News
& Events

Current News & Events | Archived News & Events
03/16/2020
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model​
03/12/2020
Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments​
02/28/2020
Homology Employees Tackle the PKU Diet in Solidarity with the PKU Community to Honor Rare Disease Day​
02/20/2020
Homology Medicines to Participate in Upcoming Investor and Scientific Conferences​
02/13/2020
Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders​
12/17/2019
Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU​
12/16/2019
Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care​
12/03/2019
Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer​
11/26/2019
Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs​
11/12/2019
Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights​
10/25/2019
Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision​
10/21/2019
Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies​
09/30/2019
Homology Medicines to Participate in Conferences in October​
09/03/2019
Homology Medicines to Participate at Upcoming Investor Conferences​
08/08/2019
Homology Medicines Reports Second Quarter 2019 Financial Results and Recent Highlights​
08/01/2019
Homology Medicines to Participate at Upcoming Conferences​
07/15/2019
Homology Medicines Appoints Alise Reicin, M.D., to the Board of Directors​
06/27/2019
Homology Medicines Announces Leadership Updates​
06/16/2019
Homology Medicines Presents Data Showing Single Dose HMI-102 Resulted in Long-Term Correction of PKU, Including Reduction of Phe and Increased Brain Neurotransmitters in Murine Model ​
06/13/2019
Homology Medicines to Present at JMP Securities Life Sciences Conference​
06/10/2019
Homology Medicines Initiates Phase 1/2 Study for HMI-102 Gene Therapy Candidate for Adults with PKU and Expects Initial Clinical Results by Year End 2019​
05/14/2019
Homology Medicines Announces FDA Fast Track Designation for HMI-102 Gene Therapy Development Candidate for Adults with PKU ​
05/13/2019
Homology Medicines Reports First Quarter 2019 Financial Results and Recent Highlights​
05/09/2019
Homology Medicines to Present at Bank of America Merrill Lynch Health Care Conference​
05/02/2019
Homology Medicines Presents Data from Gene Therapy and Gene Editing Programs and Manufacturing Capabilities at ASGCT Meeting​
04/30/2019
Homology Medicines Presents Data Demonstrating Suite of Novel AAV Vectors Targeted Key Cell Types for Inherited Retinal Diseases​
04/15/2019
Homology Medicines Announces Upcoming Presentations on its Gene Therapy and Gene Editing Platform and Manufacturing Capabilities at the American Society of Gene & Cell Therapy Meeting​
04/09/2019
Homology Medicines Announces Pricing of Public Offering of Common Stock​
04/08/2019
Homology Medicines Announces Proposed Public Offering of Common Stock​
04/04/2019
Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production​
04/04/2019
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU​